



**Date: 13<sup>th</sup> January, 2026.**

**To,**  
**BSE Limited,**  
**Phiroze Jeejeebhoy Towers,**  
**Dalal Street,**  
**Mumbai - 400 001**

**Scrip Code: 531569**

**Sub: Investor Presentation for the Third Quarter and Nine months ended on ended December 31, 2025.**

Dear Sir/ Madam,

Please find enclosed herewith Investor Presentation of Sanjivani Paranteral Limited highlighting the performance of the Company during the Third Quarter and Nine months ended on December 31, 2025.

Kindly take the above information on your records.

Thanking You,  
Yours Faithfully,

**For Sanjivani Paranteral Limited**

**Ravikumar Bogam**  
**Company Secretary Cum Compliance Officer**



## INVESTOR PRESENTATION

Q3 FY26





## Table of Contents

<b>05</b> Market Overview	<b>08</b> About The Company	<b>14</b> Manufacturing Facilities
<b>17</b> CDMO Key Clients	<b>19</b> Company's Segment & Revenue Mix	<b>23</b> Global Footprint
<b>25</b> <u>Product Portfolio</u>	<b>29</b> <u>Financials</u>	<b>37</b> <u>Stock Information</u>



## ■ Key Financial Highlights (Standalone)



**Q3 FY26**



Revenue from Operations  
**(up 20.3% Y-o-Y)**

**INR 208.6 mn**



EBITDA\*  
**(up by 35.7% Y-o-Y)**

**INR 38.8 mn**



PAT  
**(up by 37.8% Y-o-Y)**

**INR 26.2 mn**



Domestic & Export  
**(share in revenue)**

**23.1% & 76.9%**

\*EBITDA: includes other income

## ■ Key Financial Highlights (Standalone)

**9M FY26**



Revenue from Operations  
**(up 4.5% Y-o-Y)**

**INR 542.5 mn**



EBITDA\*  
**(up 5.3% Y-o-Y)**

**INR 89.8 mn**



PAT  
**(up 1.3% Y-o-Y)**

**INR 59.9 mn**



Domestic & Export  
**(share in revenue)**

**22.8% & 77.2%**

\*EBITDA: includes other income



## MARKET OVERVIEW



# Global Medicine Market




Use of medicines region wise, Defined Daily Doses (DDD)

Country Name/Year	2018	2019	2020	2021	2022	2023	2024E	2025E	2026E	2027E	2028E	CAGR 2024-2028
Asia-Pacific	451	461	477	507	547	538	559	580	598	618	637	3.4%
Latin America	342	357	438	447	448	461	473	484	489	496	506	1.9%
Western Europe	435	445	444	448	469	463	470	476	481	485	488	1.1%
India	354	359	370	400	390	399	412	428	443	458	474	3.5%
Africa & Middle East	385	395	393	428	425	410	413	424	434	442	451	1.9%
Eastern Europe	332	339	341	358	369	362	370	377	384	388	391	1.6%
China	255	279	271	301	308	308	323	337	349	359	369	3.7%
North America	270	272	270	281	290	290	294	299	303	306	309	1.3%
Japan	141	143	141	145	147	148	149	151	152	152	153	0.6%
<b>Total</b>	<b>2,964</b>	<b>3,049</b>	<b>3,144</b>	<b>3,316</b>	<b>3,394</b>	<b>3,378</b>	<b>3,465</b>	<b>3,556</b>	<b>3,633</b>	<b>3,704</b>	<b>3,778</b>	


Source: IQVIA Institute, Dec 2023.

# Global Medicine Market


**Defined Daily Doses (DDD) in billions**



**Global use of medicines**



**Global spending on medicine**



Source: IQVIA Institute, Dec 2023.



## ABOUT THE COMPANY




# About Us



**Sanjivani Paranteral Ltd** (BSE: 531569) is a pharmaceutical company headquartered in Mumbai and two manufacturing plants at Navi Mumbai and Dehradun, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. We cater major therapeutic/product areas encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

WHO-GMP/DIGEMID/DDA Certified Plants	2 Manufacturing Facilities	25 Countries Geographical Reach	~75% Exports Revenue	25+ years Experience	720 million Annual Tablet Capacity
84 million Annual Ampoules Capacity	12 million Annual Liquid injectables Capacity	120 million Annual B Lactam Tablet Capacity	180 million Annual B Lactam Capsule Capacity	72 million Annual Capsule Capacity	48 million Annual Vial Capacity

## Significant Milestones of Sanjivani Paranteral Ltd.



Years are mentioned as calendar years

## Vision of the Company

### VISION

To be one of India's best research-based pharmaceutical companies, through focus on quality and customer satisfaction.

To bring forth a new paradigm of products & services which lead to unprecedented growth for our stakeholders, customers, strategic partners & team members.

To grow the company on the foundation of Passion, Performance & Partnership.

### MISSION

Creating a world-class organization offering products, services & paradigms that open up new worlds of opportunities.



### VALUES

#### 1. Quality

Products that we are proud of

#### 2. Customer Satisfaction

Ensuring customer delight

#### 3. Growth for all stakeholders

Exceeding stakeholders' expectations is our success mantra

#### 4. Professionalism

People you love to work with. A culture of innovative thinking, backed by disciplined execution

## Sanjivani Paranteral's Competitive Advantage



We have a compact and highly adaptable presence in India, allowing us to be exceptionally nimble and agile

Our long-standing presence in the industry has established us as a respected leader, making us a preferred partner for top talent and reputable suppliers

As pioneers in injectable manufacturing in India, we have navigated the industry's regulatory evolution from its early, less stringent days. This experience allows us to effortlessly adapt to current standards

Our long-standing experience in injectable manufacturing has equipped us with a comprehensive understanding of diverse production processes, allowing us to consistently optimize for efficiency.

Rapid decision-making capabilities

## Experienced Management



Mr. Ashwani Khemka  
Chairman & Managing Director



Mr. Basant Srivastava  
Director



Mr. Srivardhan Khemka  
Executive Director



Mr. Abhay Shah  
Independent Director



Ms. Monika A. Singhania  
Independent Director



Mr. Pritesh Jain  
Chief Financial Officer



## MANUFACTURING FACILITIES



## Manufacturing Plant – Alevia HealthCare, Czech Republic



## IV Manufacturing Plant – SPL Infusion Private Limited, Pune





## CDMO KEY CLIENTS



## ■ CDMO Key Clients



## Injectables



Kopran

## Oral & Nutraceuticals






## COMPANY'S SEGMENT & REVENUE MIX




## Product Category Mix (%) | Standalone


**Q3 FY26**




**Q3 FY25**



**9M FY26**




**9M FY25**




## Geographical Mix (%) | Standalone


**Q3 FY26**




**Q3 FY25**



**9M FY26**




**9M FY25**



## Region-wise Mix (%)


### Q3 FY26

- Middle East & Africa
- India & Subcontinent
- Latin America
- CIS Countries




### Q3 FY25

- Middle East & Africa
- India & Subcontinent
- Latin America
- CIS Countries




### 9M FY26

- Middle East & Africa
- India & Subcontinent
- Latin America
- CIS Countries



### 9M FY25

- Middle East & Africa
- India & Subcontinent
- Latin America
- CIS Countries






## GLOBAL FOOTPRINT



## Global Footprint




Dehradun, Navi Mumbai, Pune & Prague



## PRODUCT PORTFOLIO



# Product Portfolio



# Product Portfolio



# Product Portfolio

Non-opioid  
Analgesics



Antacids



Antiseptics



Nsaids



Corticosteroids



Diuretics



Immunosuppressants



Narcotic



Hormone



Topical  
Corticosteroids



Anti Anxiety



Antibiotic



Antipsychotic



Anti Viral



Narcotics



Anti- Muscle  
Relaxant






## FINANCIALS




## Segment-wise Revenue

(Injectables, Oral & Nutraceuticals) INR Mn


### INJECTABLES



### ORALS




### NUTRACEUTICALS




## Segment-wise Revenue

(Injectables, Oral & Nutraceuticals) INR Mn


### INJECTABLES



### ORALS



### NUTRACEUTICALS




## Quarterly Financials


Revenue, EBITDA & Margin, PAT & Margin

INR Mn.


REVENUE\*




EBITDA\*\* & EBITDA Margin



PBT & PBT Margin



PAT & PAT Margin




\*Revenue from Operations (excluding other income) \*\*EBITDA: Including other income

## Quarterly Financials


Revenue, EBITDA & Margin, PAT & Margin

INR Mn.


REVENUE\*




EBITDA\*\* & EBITDA Margin



PBT & PBT Margin



PAT & PAT Margin



\*Revenue from Operations (excluding other income) \*\*EBITDA: Including other income


## Q3 FY26 Profit & Loss Statement

Particulars	Q3 FY26	Q3 FY25	YoY%	Q2 FY26	QoQ%	9MFY26	9MFY25	YoY%
Revenue From Operations	208.6	173.5	20.3%	155.0	34.6%	542.5	519.2	4.5%
Other Income	2.9	3.1	-6.8%	1.6	77.2%	4.9	7.9	-37.7%
<b>Total Income</b>	<b>211.5</b>	<b>176.6</b>	<b>19.8%</b>	<b>156.6</b>	<b>35.1%</b>	<b>547.4</b>	<b>527.0</b>	<b>3.9%</b>
COGS	141.9	99.3	42.9%	103.4	37.2%	356.4	310.9	14.6%
<b>Gross Profit</b>	<b>69.7</b>	<b>77.3</b>	<b>-9.9%</b>	<b>53.3</b>	<b>30.9%</b>	<b>191.1</b>	<b>216.1</b>	<b>-11.6%</b>
<b>Gross Margin (%)</b>	<b>33.4%</b>	<b>44.6%</b>	<b>-1116 bps</b>	<b>34.4%</b>	<b>-96 bps</b>	<b>35.2%</b>	<b>41.6%</b>	<b>-641 bps</b>
Employee Benefit Exp.	16.2	16.5	-1.3%	14.9	8.7%	46.4	43.9	5.7%
Other Expenses	14.6	32.2	-54.7%	14.2	2.7%	54.9	87.0	-36.9%
<b>EBITDA incl. other income</b>	<b>38.8</b>	<b>28.6</b>	<b>35.7%</b>	<b>24.1</b>	<b>61.2%</b>	<b>89.8</b>	<b>85.3</b>	<b>5.3%</b>
<b>EBITDA Margin (%)</b>	<b>18.4%</b>	<b>16.2%</b>	<b>216 bps</b>	<b>15.4%</b>	<b>297 bps</b>	<b>16.4%</b>	<b>16.2%</b>	<b>22 bps</b>
Depreciation	1.9	1.6	17.5%	1.7	10.9%	5.2	4.4	18.7%
Finance Cost	2.1	1.9	7.6%	0.5	320.6%	4.8	3.9	22.3%
PBT	34.9	25.1	39.0%	21.9	59.2%	79.8	77.0	3.7%
Tax	8.7	6.1	42.8%	5.5	57.6%	20.0	17.9	11.4%
<b>PAT</b>	<b>26.2</b>	<b>19.0</b>	<b>37.8%</b>	<b>16.4</b>	<b>59.7%</b>	<b>59.9</b>	<b>59.1</b>	<b>1.3%</b>
<b>PAT Margin (%)</b>	<b>12.4%</b>	<b>10.7%</b>	<b>162 bps</b>	<b>10.5%</b>	<b>191 bps</b>	<b>10.9%</b>	<b>11.2%</b>	<b>-28 bps</b>
Basic EPS (in Rs.)	2.13	1.62	31.1%	1.33	59.7%	4.87	5.06	-2.7%
Diluted EPS (in Rs.)	2.13	1.62		1.33		4.87	5.06	

## Q3 FY26 Profit & Loss Statement (Consolidated)


Particulars	Q3 FY26	Q3 FY25	YoY%	Q2 FY26	QoQ%	9MFY26	9MFY25	YoY%
Revenue From Operations	220.6	173.5	27.2%	155	42.4%	554.5	519.2	6.8%
Other Income	3.0	3.1	-5.4%	1.6	80.0%	4.9	7.9	-37.1%
<b>Total Income</b>	<b>223.6</b>	<b>176.6</b>	<b>26.6%</b>	<b>156.6</b>	<b>42.8%</b>	<b>559.5</b>	<b>527</b>	<b>6.2%</b>
COGS	147.3	99.3	48.4%	103.4	42.6%	361.8	310.9	16.4%
<b>Gross Profit</b>	<b>76.2</b>	<b>77.3</b>	<b>-1.4%</b>	<b>53.3</b>	<b>43.2%</b>	<b>197.6</b>	<b>216.1</b>	<b>-8.6%</b>
<b>Gross Margin (%)</b>	<b>34.6%</b>	<b>44.6%</b>	<b>-1001 bps</b>	<b>34.4%</b>	<b>19 bps</b>	<b>35.6%</b>	<b>41.6%</b>	<b>-599 bps</b>
Employee Benefit Exp.	17.6	16.5	6.7%	14.9	17.5%	47.7	43.9	8.7%
Other Expenses	17.3	32.2	-46.2%	14.2	22.0%	57.7	87	-33.7%
<b>EBITDA incl. other income</b>	<b>41.3</b>	<b>28.6</b>	<b>44.4%</b>	<b>24.1</b>	<b>71.6%</b>	<b>92.3</b>	<b>85.3</b>	<b>8.2%</b>
<b>EBITDA Margin (%)</b>	<b>18.5%</b>	<b>16.2%</b>	<b>229 bps</b>	<b>15.4%</b>	<b>310 bps</b>	<b>16.5%</b>	<b>16.2%</b>	<b>32 bps</b>
Depreciation	2.3	1.6	43.0%	1.7	34.9%	5.6	4.4	28.0%
Finance Cost	2.1	1.9	7.6%	0.5	320.6%	4.8	3.9	22.3%
PBT	37.0	25.1	47.4%	21.9	68.7%	81.9	77.0	6.4%
Tax	9.2	6.1	51.0%	5.5	66.7%	20.5	17.9	14.2%
<b>PAT</b>	<b>27.8</b>	<b>19.0</b>	<b>46.2%</b>	<b>16.4</b>	<b>69.4%</b>	<b>61.5</b>	<b>59.1</b>	<b>4.0%</b>
<b>PAT Margin (%)</b>	<b>12.4%</b>	<b>10.7%</b>	<b>167 bps</b>	<b>10.5%</b>	<b>196 bps</b>	<b>11.0%</b>	<b>11.2%</b>	<b>-23 bps</b>
Basic EPS (in Rs.)	2.21	1.62	39.1%	1.33	69.4%	4.95	5.06	-0.1%
Diluted EPS (in Rs.)	2.21	1.62		1.33		4.95	5.06	

## Long Term Growth Drivers




## Stock Information

Shareholding Pattern % as on 31<sup>st</sup> December 2025



Stock Information (as on 31<sup>st</sup> December 2025)

Market Cap. (in Bn)	2.8
Stock Price	231
52 Week (High / Low)	383 / 182
BSE – Symbol	531569
Free Float (No. of Shares)	84,51,239
Average Daily Volume (3 months) - BSE	7600





# THANK YOU

**Sanjivani Paranteral Limited**

205, P.N.Kothari Industrial Estate, L.B.S.  
Marg Bhandup (W), Mumbai- 400078, India.

Ph: +91-22-20812600 / 25620515

Email: [corporate@sanjivani.co.in](mailto:corporate@sanjivani.co.in)